应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TNXP Tonix Pharmaceuticals Holding Co
休市中 12-05 16:00:00 EST
19.64
+0.11
+0.56%
盘后
19.88
+0.24
+1.22%
19:59 EST
最高
20.24
最低
19.21
成交量
59.33万
今开
19.30
昨收
19.53
日振幅
5.26%
总市值
2.31亿
流通市值
2.25亿
总股本
1,178万
成交额
1,169万
换手率
5.17%
流通股本
1,147万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症
美股速递 · 11-24
Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症
Tonix Pharmaceuticals宣布Tonmya™(盐酸环托品舌下片)在美国商业上市,成为首个治疗纤维肌痛的创新药物
美股速递 · 11-17
Tonix Pharmaceuticals宣布Tonmya™(盐酸环托品舌下片)在美国商业上市,成为首个治疗纤维肌痛的创新药物
Tonix Pharmaceuticals与麻省总医院合作推进Tnx-1500抗Cd40l单抗二期临床试验以预防肾移植器官排斥
美股速递 · 11-04
Tonix Pharmaceuticals与麻省总医院合作推进Tnx-1500抗Cd40l单抗二期临床试验以预防肾移植器官排斥
Tonix Pharmaceuticals宣布首位患者在马萨诸塞州综合医院进行的研究中接受Tonix鼻用助效催产素的第一次给药
美股速递 · 10-22
Tonix Pharmaceuticals宣布首位患者在马萨诸塞州综合医院进行的研究中接受Tonix鼻用助效催产素的第一次给药
Tonix Pharmaceuticals任命Ganesh Kamath为市场准入负责人,进一步充实商业领导团队
美股速递 · 09-30
Tonix Pharmaceuticals任命Ganesh Kamath为市场准入负责人,进一步充实商业领导团队
Tonix Pharmaceuticals计划在2026年启动Tnx-2900(鼻内增强催产素)治疗普拉德-威利综合征的2期临床试验
美股速递 · 09-29
Tonix Pharmaceuticals计划在2026年启动Tnx-2900(鼻内增强催产素)治疗普拉德-威利综合征的2期临床试验
Tonix Pharmaceuticals宣布TNX-102 SL治疗重度抑郁症的FDA预IND会议获得积极结果
美股速递 · 09-18
Tonix Pharmaceuticals宣布TNX-102 SL治疗重度抑郁症的FDA预IND会议获得积极结果
Tonix Pharmaceuticals宣布授权引入已准备进入2/3期临床试验的单克隆抗体,用于季节性预防莱姆病(Tnx-4800)
美股速递 · 09-17
Tonix Pharmaceuticals宣布授权引入已准备进入2/3期临床试验的单克隆抗体,用于季节性预防莱姆病(Tnx-4800)
盘前异动 | TNXP飙升11%,迅雷涨超15%!BMNR等加密股走低
老虎资讯综合 · 08-18
盘前异动 | TNXP飙升11%,迅雷涨超15%!BMNR等加密股走低
美股异动丨Tonix盘前涨超10%
格隆汇 · 08-18
美股异动丨Tonix盘前涨超10%
异动解读 | Tonix制药夜盘大涨18.79%,FDA批准其纤维肌痛新药
异动解读 · 08-18
异动解读 | Tonix制药夜盘大涨18.79%,FDA批准其纤维肌痛新药
美国FDA批准Tonix Pharmaceuticals用于治疗慢性病相关疼痛的药物
老虎资讯综合 · 08-18
美国FDA批准Tonix Pharmaceuticals用于治疗慢性病相关疼痛的药物
异动解读 | 托尼克斯制药盘前大涨7.28%,尽管季度业绩不及预期,分析师仍看好前景
异动解读 · 08-15
异动解读 | 托尼克斯制药盘前大涨7.28%,尽管季度业绩不及预期,分析师仍看好前景
异动解读 | 托尼克斯制药盘前大涨7.28%,尽管季度业绩不及预期,分析师仍看好前景
异动解读 · 08-15
异动解读 | 托尼克斯制药盘前大涨7.28%,尽管季度业绩不及预期,分析师仍看好前景
异动解读 | 托尼克斯制药夜盘大涨5.74%,尽管季度业绩不及预期
异动解读 · 08-15
异动解读 | 托尼克斯制药夜盘大涨5.74%,尽管季度业绩不及预期
Tonix Pharmaceuticals二季度每股亏损高于预期,营收低于预期
异动解读 · 08-15
Tonix Pharmaceuticals二季度每股亏损高于预期,营收低于预期
Tonix Pharmaceuticals Holding Corp.盘中异动 早盘股价大跌5.02%报10.40美元
市场透视 · 02-19
Tonix Pharmaceuticals Holding Corp.盘中异动 早盘股价大跌5.02%报10.40美元
Tonix Pharmaceuticals Holding Corp.盘中异动 大幅下挫5.02%
市场透视 · 02-18
Tonix Pharmaceuticals Holding Corp.盘中异动 大幅下挫5.02%
Tonix Pharmaceuticals Holding Corp.盘中异动 早盘急速上涨5.04%
市场透视 · 02-13
Tonix Pharmaceuticals Holding Corp.盘中异动 早盘急速上涨5.04%
Tonix Pharmaceuticals Holding Corp.盘中异动 大幅跳水5.11%报11.33美元
市场透视 · 02-11
Tonix Pharmaceuticals Holding Corp.盘中异动 大幅跳水5.11%报11.33美元
加载更多
公司概况
公司名称:
Tonix Pharmaceuticals Holding Co
所属市场:
NASDAQ
上市日期:
--
主营业务:
Tonix Pharmaceuticals Holding Corp.2007年11月16日在内华达州成立。该公司是一家临床阶段的生物制药公司,专注于开发治疗和预防人类疾病和减轻痛苦的疗法和疫苗。该公司拥有大量正在开发的产品,这些产品是通过内部发现、许可、收购以及与学术机构和合同研究组织的合作来策划的。公司继续在合成生物学、精准医学、蛋白质工程、药物化学、分子生物学、药物基因组学和临床规模制造方面建设能力。该公司正在开发的疗法包括小分子和生物制剂。
发行价格:
--
{"stockData":{"symbol":"TNXP","market":"US","secType":"STK","nameCN":"Tonix Pharmaceuticals Holding Co","latestPrice":19.64,"timestamp":1764968400000,"preClose":19.53,"halted":0,"volume":593325,"hourTrading":{"tag":"盘后","latestPrice":19.88,"preClose":19.64,"latestTime":"19:59 EST","volume":4074,"amount":80506.0893,"timestamp":1764982777227},"delay":0,"floatShares":11470800,"shares":11776542,"eps":-20.180584,"marketStatus":"休市中","change":0.11,"latestTime":"12-05 16:00:00 EST","open":19.3,"high":20.24,"low":19.2119,"amount":11693367.171675,"amplitude":0.052642,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-20.180584,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":19.53,"preHourTrading":{"tag":"盘前","latestPrice":19.34,"preClose":19.53,"latestTime":"09:29 EST","volume":6865,"amount":134783.462625,"timestamp":1764944992214},"postHourTrading":{"tag":"盘后","latestPrice":19.88,"preClose":19.64,"latestTime":"19:59 EST","volume":4074,"amount":80506.0893,"timestamp":1764982777227},"volumeRatio":0.840244,"impliedVol":1.2347,"impliedVolPercentile":0.0909},"requestUrl":"/m/hq/s/TNXP","defaultTab":"news","newsList":[{"id":"1165886549","title":"Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症","url":"https://stock-news.laohu8.com/highlight/detail?id=1165886549","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165886549?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:02","pubTimestamp":1763985760,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"1166751996","title":"Tonix Pharmaceuticals宣布Tonmya™(盐酸环托品舌下片)在美国商业上市,成为首个治疗纤维肌痛的创新药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1166751996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166751996?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:01","pubTimestamp":1763380901,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布Tonmya™(盐酸环托品舌下片)在美国商业上市,成为首个治疗纤维肌痛的创新药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0},{"id":"1146414586","title":"Tonix Pharmaceuticals与麻省总医院合作推进Tnx-1500抗Cd40l单抗二期临床试验以预防肾移植器官排斥","url":"https://stock-news.laohu8.com/highlight/detail?id=1146414586","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146414586?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:01","pubTimestamp":1762257661,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals与麻省总医院合作,推进其二期临床试验,研究二聚体Fc改造的抗Cd40l单抗Tnx-1500,以预防肾脏移植中的器官排斥反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"1107329917","title":"Tonix Pharmaceuticals宣布首位患者在马萨诸塞州综合医院进行的研究中接受Tonix鼻用助效催产素的第一次给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1107329917","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107329917?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:01","pubTimestamp":1761130884,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布首位患者在由马萨诸塞州综合医院进行的调查者发起的焦点研究中接受Tonix鼻用助效催产素的第一次给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0},{"id":"1148493950","title":"Tonix Pharmaceuticals任命Ganesh Kamath为市场准入负责人,进一步充实商业领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1148493950","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148493950?lang=zh_cn&edition=full","pubTime":"2025-09-30 20:33","pubTimestamp":1759235588,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals任命Ganesh Kamath为市场准入负责人,进一步充实商业领导团队","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"1193478502","title":"Tonix Pharmaceuticals计划在2026年启动Tnx-2900(鼻内增强催产素)治疗普拉德-威利综合征的2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1193478502","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193478502?lang=zh_cn&edition=full","pubTime":"2025-09-29 19:04","pubTimestamp":1759143856,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals计划在2026年启动Tnx-2900(鼻内增强催产素)治疗普拉德-威利综合征的2期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"1174825720","title":"Tonix Pharmaceuticals宣布TNX-102 SL治疗重度抑郁症的FDA预IND会议获得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174825720","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174825720?lang=zh_cn&edition=full","pubTime":"2025-09-18 20:00","pubTimestamp":1758196828,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布TNX-102 SL治疗重度抑郁症的FDA预IND会议获得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0},{"id":"1196311138","title":"Tonix Pharmaceuticals宣布授权引入已准备进入2/3期临床试验的单克隆抗体,用于季节性预防莱姆病(Tnx-4800)","url":"https://stock-news.laohu8.com/highlight/detail?id=1196311138","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196311138?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106891,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布授权引入已准备进入2/3期临床试验的单克隆抗体,用于季节性预防莱姆病(Tnx-4800)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"1175517857","title":"盘前异动 | TNXP飙升11%,迅雷涨超15%!BMNR等加密股走低","url":"https://stock-news.laohu8.com/highlight/detail?id=1175517857","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175517857?lang=zh_cn&edition=full","pubTime":"2025-08-18 16:14","pubTimestamp":1755504855,"startTime":"0","endTime":"0","summary":"8月18日,美股三大股指期货下跌,截止发稿,道指期货跌0.29%,纳指期货跌0.03%,标普500指数期货跌0.13%。$诺和诺德$涨超3%,Wegovy获FDA批准用于治疗肝病。$Tonix Pharmaceuticals$涨超11%,其纤维肌痛新药获FDA批准。部分中概股走高,$迅雷$涨超15%,$爱奇艺$涨超9%,$金山云$涨近6%,$理想汽车$、$小鹏汽车$、$蔚来$涨超1%。加密概念股下挫,$Upexi$、$BitMine$跌超4%,$SharpLink$跌超3%,$Bit Digital$、$Strategy$、$MARA Holdings$跌超2%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BMNR","IQ","BK4147","BK4023","NVO","LI","BK4139","BK4099","SHCO","BK4563","SBET","MSTR.AU","BK4583","XPEV","XNET","NIO","NVO.AU","KC","MSTR","LU1093756168.USD","UPXI","MARA","BK4116","BK4585","BK4526","BK4531","TNXP","BTBT"],"gpt_icon":0},{"id":"2560977506","title":"美股异动丨Tonix盘前涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560977506","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560977506?lang=zh_cn&edition=full","pubTime":"2025-08-18 16:12","pubTimestamp":1755504761,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ad16bf258724617c5157afa8ededbfd2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["TNXP","BK4139","BK4583"],"gpt_icon":0},{"id":"1103633394","title":"异动解读 | Tonix制药夜盘大涨18.79%,FDA批准其纤维肌痛新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1103633394","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103633394?lang=zh_cn&edition=full","pubTime":"2025-08-18 08:26","pubTimestamp":1755476783,"startTime":"0","endTime":"0","summary":"周日夜盘交易中,Tonix Pharmaceuticals Holding Co股价大幅上涨18.79%,引发市场广泛关注。这一显著涨幅主要源于该公司重大利好消息的公布。据悉,美国食品和药物管理局已批准Tonix制药用于治疗纤维肌痛相关疼痛的新药。这款名为Tonmya的非阿片类药物是15年来首个获批用于纤维肌痛治疗的新药,为患者提供了新的治疗选择。考虑到目前纤维肌痛治疗市场存在巨大缺口,Tonix制药此次获批无疑为公司开辟了广阔的市场空间,这也解释了投资者对公司股票的热烈追捧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TNXP"],"gpt_icon":0},{"id":"1102966918","title":"美国FDA批准Tonix Pharmaceuticals用于治疗慢性病相关疼痛的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1102966918","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102966918?lang=zh_cn&edition=full","pubTime":"2025-08-18 08:22","pubTimestamp":1755476576,"startTime":"0","endTime":"0","summary":"$Tonix Pharmaceuticals Holding Co$ 上周五表示,美国食品和药物管理局已批准其用于治疗一种名为纤维肌痛的慢性病相关疼痛的药物。此次获批为该药成为15年多来纤维肌痛患者的首个新治疗选择铺平了道路。这种非阿片类药物将以Tonmya为品牌名销售,是一种专为睡前治疗设计的药片,旨在改善睡眠质量并减轻这种慢性病相关的疼痛。Tonix向卫生监管机构提交的申请基于两项后期研究。扎克斯小盘股研究公司分析师戴维·鲍茨表示,这对Tonix来说是一个巨大的机会。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/12d14980c1b27536197b89096219ad7a","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/12d14980c1b27536197b89096219ad7a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美国FDA批准Tonix Pharmaceuticals用于治疗慢性病相关疼痛的药物","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP"],"gpt_icon":1},{"id":"1107491031","title":"异动解读 | 托尼克斯制药盘前大涨7.28%,尽管季度业绩不及预期,分析师仍看好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1107491031","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107491031?lang=zh_cn&edition=full","pubTime":"2025-08-15 16:04","pubTimestamp":1755245087,"startTime":"0","endTime":"0","summary":"美国生物制药公司托尼克斯制药控股公司周五盘前大涨7.28%,引发市场广泛关注。这一显著涨幅出现在公司发布第二季度财报后,尽管财报显示业绩不及预期。根据最新发布的财报,托尼克斯制药第二季度调整后每股亏损3.86美元,高于分析师预期的3.21美元亏损。值得注意的是,尽管季度业绩欠佳,托尼克斯制药的股价表现依然强劲。分析师给予托尼克斯制药12个月目标价中位数为65.00美元,较前一交易日收盘价高出约5.3%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TNXP"],"gpt_icon":1},{"id":"1176210092","title":"异动解读 | 托尼克斯制药盘前大涨7.28%,尽管季度业绩不及预期,分析师仍看好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1176210092","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176210092?lang=zh_cn&edition=full","pubTime":"2025-08-15 16:04","pubTimestamp":1755245081,"startTime":"0","endTime":"0","summary":"美国生物制药公司托尼克斯制药控股公司周五盘前大涨7.28%,引发市场广泛关注。这一显著涨幅出现在公司发布第二季度财报后,尽管业绩不及预期,但投资者似乎对公司的长期发展前景保持乐观。尽管季度业绩表现不佳,托尼克斯制药的股价本季度已累计上涨71.1%,今年迄今为止更是上涨了86.7%,显示出投资者对公司的持续信心。值得注意的是,尽管季度业绩不及预期,分析师仍对托尼克斯制药保持积极态度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TNXP"],"gpt_icon":0},{"id":"1195697390","title":"异动解读 | 托尼克斯制药夜盘大涨5.74%,尽管季度业绩不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1195697390","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195697390?lang=zh_cn&edition=full","pubTime":"2025-08-15 13:43","pubTimestamp":1755236591,"startTime":"0","endTime":"0","summary":"尽管公布的季度业绩不及预期,托尼克斯制药控股公司周五夜盘仍大涨5.74%,引发市场关注。根据公司最新发布的财报,截至6月30日的季度调整后每股亏损为3.86美元,高于分析师预期的3.21美元亏损。尽管业绩表现不佳,但投资者似乎对公司的长期前景保持乐观。值得注意的是,尽管季度业绩不佳,托尼克斯制药的股价本季度已累计上涨71.1%,今年迄今为止更是上涨了86.7%。这种乐观情绪可能是推动股价在财报发布后继续上涨的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TNXP"],"gpt_icon":0},{"id":"1197205414","title":"Tonix Pharmaceuticals二季度每股亏损高于预期,营收低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1197205414","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197205414?lang=zh_cn&edition=full","pubTime":"2025-08-15 13:43","pubTimestamp":1755236591,"startTime":"0","endTime":"0","summary":"第二季度调整后每股亏损3.86美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP"],"gpt_icon":0},{"id":"2512836904","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 早盘股价大跌5.02%报10.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512836904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512836904?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:32","pubTimestamp":1739975548,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时32分,Tonix Pharmaceuticals Holding Corp.股票出现波动,股价大幅跳水5.02%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中,整体涨幅为0.00%。Tonix Pharmaceuticals Holding Corp.公司简介:Tonix Pharmaceuticals Holding Corp 是一家生物制药公司,专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223229abd4fe6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223229abd4fe6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0},{"id":"2512165045","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 大幅下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165045?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:43","pubTimestamp":1739889789,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时43分,Tonix Pharmaceuticals Holding Corp.股票出现异动,股价快速下跌5.02%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中,整体涨幅为0.60%。Tonix Pharmaceuticals Holding Corp.公司简介:Tonix Pharmaceuticals Holding Corp 是一家生物制药公司,专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224309a24aaf63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224309a24aaf63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TNXP","BK4583","BK4139"],"gpt_icon":0},{"id":"2511524392","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 早盘急速上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511524392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511524392?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:22","pubTimestamp":1739460145,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时22分,Tonix Pharmaceuticals Holding Corp.股票出现异动,股价大幅上涨5.04%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中,整体涨幅为0.21%。Tonix Pharmaceuticals Holding Corp.公司简介:Tonix Pharmaceuticals Holding Corp 是一家生物制药公司,专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232226a244b66b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232226a244b66b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TNXP","BK4139","BK4583"],"gpt_icon":0},{"id":"2510387287","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 大幅跳水5.11%报11.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510387287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510387287?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:33","pubTimestamp":1739284405,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时33分,Tonix Pharmaceuticals Holding Corp.股票出现异动,股价快速下跌5.11%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中,整体跌幅为0.95%。Tonix Pharmaceuticals Holding Corp.公司简介:Tonix Pharmaceuticals Holding Corp 是一家生物制药公司,专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112233259881bd37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112233259881bd37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tonixpharma.com;www.tonix.com","stockEarnings":[{"period":"1week","weight":0.2298},{"period":"1month","weight":0.0839},{"period":"3month","weight":-0.26},{"period":"6month","weight":-0.5169},{"period":"1year","weight":0.1386},{"period":"ytd","weight":-0.4045}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tonix Pharmaceuticals Holding Corp.2007年11月16日在内华达州成立。该公司是一家临床阶段的生物制药公司,专注于开发治疗和预防人类疾病和减轻痛苦的疗法和疫苗。该公司拥有大量正在开发的产品,这些产品是通过内部发现、许可、收购以及与学术机构和合同研究组织的合作来策划的。公司继续在合成生物学、精准医学、蛋白质工程、药物化学、分子生物学、药物基因组学和临床规模制造方面建设能力。该公司正在开发的疗法包括小分子和生物制剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.198055},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.159356},{"month":3,"riseRate":0.416667,"avgChangeRate":0.038421},{"month":4,"riseRate":0.25,"avgChangeRate":-0.073521},{"month":5,"riseRate":0.416667,"avgChangeRate":0.017213},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.071625},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.11658},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.140207},{"month":9,"riseRate":0.153846,"avgChangeRate":-0.25769},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.06224},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.060378},{"month":12,"riseRate":0.615385,"avgChangeRate":0.072092}],"exchange":"NASDAQ","name":"Tonix Pharmaceuticals Holding Co","nameEN":"Tonix Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tonix Pharmaceuticals Holding Co(TNXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tonix Pharmaceuticals Holding Co,TNXP,Tonix Pharmaceuticals Holding Co股票,Tonix Pharmaceuticals Holding Co股票老虎,Tonix Pharmaceuticals Holding Co股票老虎国际,Tonix Pharmaceuticals Holding Co行情,Tonix Pharmaceuticals Holding Co股票行情,Tonix Pharmaceuticals Holding Co股价,Tonix Pharmaceuticals Holding Co股市,Tonix Pharmaceuticals Holding Co股票价格,Tonix Pharmaceuticals Holding Co股票交易,Tonix Pharmaceuticals Holding Co股票购买,Tonix Pharmaceuticals Holding Co股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tonix Pharmaceuticals Holding Co(TNXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}